Neurofilament light chain (NfL) has proven its value in multiple sclerosis (MS) as a biomarker not only of disease activity through its correlation with relapse rate and presence of gadolinium-enhancing lesions, but also for prognosis and treatment response [5]. This evidence concerns the gene NEFL and myeloid sarcoma.